Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $181.71.

A number of research firms have recently commented on JAZZ. Piper Sandler restated an "overweight" rating and issued a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Wall Street Zen lowered shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Royal Bank Of Canada cut their target price on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, Robert W. Baird reduced their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th.

Jazz Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ JAZZ opened at $112.65 on Tuesday. The firm's 50-day moving average is $109.31 and its two-hundred day moving average is $118.15. The company has a market capitalization of $6.82 billion, a PE ratio of 15.02, a price-to-earnings-growth ratio of 5.64 and a beta of 0.32. Jazz Pharmaceuticals has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a debt-to-equity ratio of 1.28, a current ratio of 3.38 and a quick ratio of 2.97.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The company's revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.68 EPS. Equities analysts anticipate that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total transaction of $116,350.00. Following the completion of the sale, the chief executive officer owned 439,307 shares of the company's stock, valued at approximately $51,113,369.45. This trade represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Seamus Mulligan bought 100,000 shares of the stock in a transaction on Friday, May 9th. The stock was acquired at an average cost of $98.26 per share, for a total transaction of $9,826,000.00. Following the acquisition, the director directly owned 100,000 shares in the company, valued at approximately $9,826,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders sold 2,500 shares of company stock worth $277,930. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC grew its holdings in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares during the period. Hurley Capital LLC bought a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth $25,000. Elequin Capital LP grew its stake in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 183 shares during the period. CoreFirst Bank & Trust acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $28,000. Finally, Allianz SE bought a new position in Jazz Pharmaceuticals during the fourth quarter worth about $29,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.